Cargando…

Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis

RATIONALE: The monitoring of TB treatments in clinical practice and clinical trials relies on traditional sputum-based culture status indicators at specific time points. Accurate, predictive, blood-based protein markers would provide a simpler and more informative view of patient health and response...

Descripción completa

Detalles Bibliográficos
Autores principales: Kedia, Komal, Wendler, Jason P., Baker, Erin S., Burnum-Johnson, Kristin E., Jarsberg, Leah G., Stratton, Kelly G., Wright, Aaron T., Piehowski, Paul D., Gritsenko, Marina A., Lewinsohn, David M., Sigal, George B., Weiner, Marc H., Smith, Richard D., Jacobs, Jon M., Nahid, Payam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181582/
https://www.ncbi.nlm.nih.gov/pubmed/30205969
http://dx.doi.org/10.1016/j.tube.2018.07.005
_version_ 1783362431763873792
author Kedia, Komal
Wendler, Jason P.
Baker, Erin S.
Burnum-Johnson, Kristin E.
Jarsberg, Leah G.
Stratton, Kelly G.
Wright, Aaron T.
Piehowski, Paul D.
Gritsenko, Marina A.
Lewinsohn, David M.
Sigal, George B.
Weiner, Marc H.
Smith, Richard D.
Jacobs, Jon M.
Nahid, Payam
author_facet Kedia, Komal
Wendler, Jason P.
Baker, Erin S.
Burnum-Johnson, Kristin E.
Jarsberg, Leah G.
Stratton, Kelly G.
Wright, Aaron T.
Piehowski, Paul D.
Gritsenko, Marina A.
Lewinsohn, David M.
Sigal, George B.
Weiner, Marc H.
Smith, Richard D.
Jacobs, Jon M.
Nahid, Payam
author_sort Kedia, Komal
collection PubMed
description RATIONALE: The monitoring of TB treatments in clinical practice and clinical trials relies on traditional sputum-based culture status indicators at specific time points. Accurate, predictive, blood-based protein markers would provide a simpler and more informative view of patient health and response to treatment. OBJECTIVE: We utilized sensitive, high throughput multiplexed ion mobility-mass spectrometry (IM-MS) to characterize the serum proteome of TB patients at the start of and at 8 weeks of rifamycin-based treatment. We sought to identify treatment specific signatures within patients as well as correlate the proteome signatures to various clinical markers of treatment efficacy. METHODS: Serum samples were collected from 289 subjects enrolled in CDC TB Trials Consortium Study 29 at time of enrollment and at the end of the intensive phase (after 40 doses of TB treatment). Serum proteins were immunoaffinity-depleted of high abundant components, digested to peptides and analyzed for data acquisition utilizing a unique liquid chromatography IM-MS platform (LC-IM-MS). Linear mixed models were utilized to identify serum protein changes in the host response to antibiotic treatment as well as correlations with culture status end points. RESULTS: A total of 10,137 peptides corresponding to 872 proteins were identified, quantified, and used for statistical analysis across the longitudinal patient cohort. In response to TB treatment, 244 proteins were significantly altered. Pathway/network comparisons helped visualize the interconnected proteins, identifying up regulated (lipid transport, coagulation cascade, endopeptidase activity) and down regulated (acute phase) processes and pathways in addition to other cross regulated networks (inflammation, cell adhesion, extracellular matrix). Detection of possible lung injury serum proteins such as HPSE, significantly downregulated upon treatment. Analyses of microbiologic data over time identified a core set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2) which change in response to treatment and also strongly correlate with culture status. A similar set of proteins at baseline were found to be predictive of week 6 and 8 culture status. CONCLUSION: A comprehensive host serum protein dataset reflective of TB treatment effect is defined. A repeating set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2, among others) were found to change significantly in response to treatment, to strongly correlate with culture status, and at baseline to be predictive of future culture conversion. If validated in cohorts with long term follow-up to capture failure and relapse of TB, these protein markers could be developed for monitoring of treatment in clinical trials and in patient care.
format Online
Article
Text
id pubmed-6181582
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-61815822018-10-11 Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis Kedia, Komal Wendler, Jason P. Baker, Erin S. Burnum-Johnson, Kristin E. Jarsberg, Leah G. Stratton, Kelly G. Wright, Aaron T. Piehowski, Paul D. Gritsenko, Marina A. Lewinsohn, David M. Sigal, George B. Weiner, Marc H. Smith, Richard D. Jacobs, Jon M. Nahid, Payam Tuberculosis (Edinb) Article RATIONALE: The monitoring of TB treatments in clinical practice and clinical trials relies on traditional sputum-based culture status indicators at specific time points. Accurate, predictive, blood-based protein markers would provide a simpler and more informative view of patient health and response to treatment. OBJECTIVE: We utilized sensitive, high throughput multiplexed ion mobility-mass spectrometry (IM-MS) to characterize the serum proteome of TB patients at the start of and at 8 weeks of rifamycin-based treatment. We sought to identify treatment specific signatures within patients as well as correlate the proteome signatures to various clinical markers of treatment efficacy. METHODS: Serum samples were collected from 289 subjects enrolled in CDC TB Trials Consortium Study 29 at time of enrollment and at the end of the intensive phase (after 40 doses of TB treatment). Serum proteins were immunoaffinity-depleted of high abundant components, digested to peptides and analyzed for data acquisition utilizing a unique liquid chromatography IM-MS platform (LC-IM-MS). Linear mixed models were utilized to identify serum protein changes in the host response to antibiotic treatment as well as correlations with culture status end points. RESULTS: A total of 10,137 peptides corresponding to 872 proteins were identified, quantified, and used for statistical analysis across the longitudinal patient cohort. In response to TB treatment, 244 proteins were significantly altered. Pathway/network comparisons helped visualize the interconnected proteins, identifying up regulated (lipid transport, coagulation cascade, endopeptidase activity) and down regulated (acute phase) processes and pathways in addition to other cross regulated networks (inflammation, cell adhesion, extracellular matrix). Detection of possible lung injury serum proteins such as HPSE, significantly downregulated upon treatment. Analyses of microbiologic data over time identified a core set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2) which change in response to treatment and also strongly correlate with culture status. A similar set of proteins at baseline were found to be predictive of week 6 and 8 culture status. CONCLUSION: A comprehensive host serum protein dataset reflective of TB treatment effect is defined. A repeating set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2, among others) were found to change significantly in response to treatment, to strongly correlate with culture status, and at baseline to be predictive of future culture conversion. If validated in cohorts with long term follow-up to capture failure and relapse of TB, these protein markers could be developed for monitoring of treatment in clinical trials and in patient care. 2018-07-18 2018-09 /pmc/articles/PMC6181582/ /pubmed/30205969 http://dx.doi.org/10.1016/j.tube.2018.07.005 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Article
Kedia, Komal
Wendler, Jason P.
Baker, Erin S.
Burnum-Johnson, Kristin E.
Jarsberg, Leah G.
Stratton, Kelly G.
Wright, Aaron T.
Piehowski, Paul D.
Gritsenko, Marina A.
Lewinsohn, David M.
Sigal, George B.
Weiner, Marc H.
Smith, Richard D.
Jacobs, Jon M.
Nahid, Payam
Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
title Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
title_full Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
title_fullStr Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
title_full_unstemmed Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
title_short Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
title_sort application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181582/
https://www.ncbi.nlm.nih.gov/pubmed/30205969
http://dx.doi.org/10.1016/j.tube.2018.07.005
work_keys_str_mv AT kediakomal applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT wendlerjasonp applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT bakererins applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT burnumjohnsonkristine applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT jarsbergleahg applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT strattonkellyg applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT wrightaaront applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT piehowskipauld applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT gritsenkomarinaa applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT lewinsohndavidm applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT sigalgeorgeb applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT weinermarch applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT smithrichardd applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT jacobsjonm applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis
AT nahidpayam applicationofmultiplexedionmobilityspectrometrytowardstheidentificationofhostproteinsignaturesoftreatmenteffectinpulmonarytuberculosis